Combination immunotherapy with TLR agonists and checkpoint inhibitors suppresses head and neck cancer

Checkpoint inhibitors have demonstrated efficacy in patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). However, the majority of patients do not benefit from these agents. To improve the efficacy of checkpoint inhibitors, intratumoral (i.t.) injection with innate imm...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:JCI Insight
Prif Awduron: Sato-Kaneko, Fumi, Yao, Shiyin, Ahmadi, Alast, Zhang, Shannon S., Hosoya, Tadashi, Kaneda, Megan M., Varner, Judith A., Pu, Minya, Messer, Karen S., Guiducci, Cristiana, Coffman, Robert L., Kitaura, Kazutaka, Matsutani, Takaji, Suzuki, Ryuji, Carson, Dennis A., Hayashi, Tomoko, Cohen, Ezra E.W.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: American Society for Clinical Investigation 2017
Pynciau:
Research Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC5621908/
https://ncbi.nlm.nih.gov/pubmed/28931759
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/jci.insight.93397
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg